Press release
B-cell Maturation Antigen (BCMA) Targeted Therapies Market Revenue Opportunies By Key Vendors Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus
Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/190
High unmet needs by the recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market
The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options are available for patients with recurrent cancer and hence the BCMA targeted therapies provides breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma and will also cater to the current unmet needs for the treatment of relapsed or refractory myeloma, where the existing treatment modalities have proved to be clinically inefficient.
Key players are actively developing the products which are in preclinical and clinical trials, results on these classes of therapies have demonstrated potential benefits, mainly through the safety profile offered by these therapies.
Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow. The plasma cells are a crucial part of the immune system, which helps to fight against various types of infections and several other diseases. Multiple myeloma is a type of cancer formed by malignant plasma cells and characterized by low blood counts, renal failure, hypercalcemia, immune suppression, monoclonal gammopathy, and anemia. Also, multiple myeloma remains as an incurable disease. According to the American Cancer Society, in 2017, an estimated 30,280 adults (17,490 men and 12,790 women) in the U.S. will be diagnosed with multiple myeloma and 12,590 deaths (6,660 men and 5,930 women) will occur in U.S. in 2017 due to multiple myeloma disease. According to the National Center for Biotechnology Information 2014, multiple myeloma represents 8.2% of all blood cancers in Africa.
Request a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/190
Detailed Segmentation:
Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type:
Antibody Drug Conjugates
CAR-T Cells
Bispecific Antibodies
Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication:
Acute Lymphoblastic Leukemia
Multiple Myeloma
Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Region:
North America
Overview
Epidemiology
Latin America
Overview
Epidemiology
Europe
Overview
Epidemiology
Asia Pacific
Overview
Epidemiology
Middle East
Overview
Epidemiology
Africa
Overview
Epidemiology
Company Profiles
Celgene Corporation *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
GlaxoSmithKline plc.
Novartis AG
Juno Therapeutics
Gilead Sciences. Inc
Amgen Inc
Affimed N.V
Poseida Therapeutics, Inc.
Autolus Ltd
Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/190
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
1001 4th Ave,, #3200, Seattle, WA 98154
#3200
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-cell Maturation Antigen (BCMA) Targeted Therapies Market Revenue Opportunies By Key Vendors Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus here
News-ID: 1261195 • Views: …
More Releases from Coherent Market Insights - Biotechnology
Wearable Patch Market 2030 Emerging Trends and Global Demand During the COVID-19 …
Coherent Market Insights published a report, titled,"Wearable Patch Market, by Technology (Connected and Regular), by Application (Monitoring, Drug Delivery, and Diagnostics), by End User (Healthcare and Fitness & Sports), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027."
Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial…
Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used…
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness…
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies.
Free Request Sample Copy…
More Releases for BCMA
BCMA/CD3 Bispecific Antibody Market Share Driven by Breakthroughs in Targeted Im …
BCMA/CD3 Bispecific Antibody Market
BCMA/CD3 targeted drug is a bispecific antibody drug used to treat multiple myeloma. It simultaneously targets B cell maturation antigen (BCMA) and CD3 molecules on the surface of T cells, directing T cells to cancer cells, thereby enhancing the killing effect on cancer cells.
The global BCMA/CD3 Bispecific Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a…
Targeting Tomorrow: Advancements and Opportunities in the BCMA-Targeted Therapy …
In today's dynamic global economy, the B cell maturation antigen targeted therapy market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to…
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Opportunitie …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global b-cell maturation antigen (bcma) targeted therapies market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was…
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
* Research Methodology
* Global and Regional Market Analysis
* Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
* Market and Drug Sales Insight 2020 Till 2026
* Approved Drug In Market: 2 Drugs
* Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
* Future Market Assessment By Indication Till 2026
*…
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2022 | Detailed Repor …
The B-Cell Maturation Antigen (BCMA) Targeted Therapies research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
